Subject: RE: BFP for Novavax Contract-Georgia
From: Tamar Gabunia <[email-masked]>
To: Tania Dmytraczenko <[email-masked]>, Sebastian-A Molineus <[email-masked]>, Volkan Cetinkaya <[email-masked]>, Nino Kvernadze <[email-masked]>, "Nino V. Moroshkina" <[email-masked]>, Enzo De Laurentiis <[email-masked]>
Cc: Ahmet Levent Yener <[email-masked]>, "[email-masked]" <[email-masked]>, "[email-masked]" <[email-masked]>, Giorgi Tsotskolauri <[email-masked]>, Maia Nikoleishvili <[email-masked]>, "[email-masked]" <[email-masked]>, Ekaterine Tikaradze <[email-masked]>
Date: Mon, 05 Apr 2021 15:32:06 +0000

Dear Tania

Many thanks for your e-mail and clarification. This is helpful to know.

პატივისცემით,

თამარ გაბუნია

მინისტრის პირველი მოადგილე

Sincerely,

Tamar Gabunia, MD, MPH

First Deputy Minister

From: Tania Dmytraczenko [mailto:[email-masked]]
Sent: 5 April, 2021 18:08
To: Sebastian-A Molineus ; Tamar Gabunia ; Volkan Cetinkaya ; Nino Kvernadze ; Nino V. Moroshkina ; Enzo De Laurentiis
Cc: Ahmet Levent Yener ; [email-masked]; [email-masked]; Giorgi Tsotskolauri ; Maia Nikoleishvili ; [email-masked]; Ekaterine Tikaradze
Subject: RE: BFP for Novavax Contract-Georgia

Dear Tamar,

Regarding utilization of Bank financing, we are seeking approval from the Board to modify the eligibility threshold for COVID-19 vaccines. The proposed eligibility threshold would allow Bank financing to be used for vaccines that have received regular or emergency licensure or authorization from at least one of the stringent regulatory authority, as identified by WHO for vaccines procured and/or supplied under the COVAX Facility, as may be amended from time to time by WHO; or WHO Emergency Use Listing (EUL).

The WHO product eligibility under the COVAX Facility currently includes the following SRAs in its list: EU-EMA, UK MHRA, Australia-TGA, Health Canada,  Switzerland-Swissmedic and USA-USFDA.

Provided the Vaccine Approval Criteria has been met, payments made by the Borrower during the 12-months period prior to signing of the financing agreement are eligible for retroactive financing for contracts that are determined to be eligible based on the Bank’s due diligence and acceptance of other provisions, such as anti-corruption clauses and audit rights.

Regards,
Tania

Tania Dmytraczenko

Practice Manager (Europe and Central Asia)

Health, Nutrition and Population Global Practice

T

202 473-8646

E

[email-masked]

dmytraczenko

A

1818 H Street, NW Washington, DC 20433

From: Sebastian-A Molineus <[email-masked]>
Sent: Monday, April 5, 2021 2:52 AM
To: [email-masked]; Volkan Cetinkaya <[email-masked]>; Nino Kvernadze <[email-masked]>; Nino V. Moroshkina <[email-masked]>; Enzo De Laurentiis <[email-masked]>
Cc: Tania Dmytraczenko <[email-masked]>; Ahmet Levent Yener <[email-masked]>; [email-masked]; [email-masked]; Giorgi Tsotskolauri <[email-masked]>; Maia Nikoleishvili <[email-masked]>; [email-masked]; Ekaterine Tikaradze <[email-masked]>
Subject: RE: BFP for Novavax Contract-Georgia

Dear Tamar –

Thank you for your message and my apologies for the slightly delayed response.

As recently discussed with our WB health team, it is great to hear that you are negotiating with the SII to procure 1m doses of Novovax.  I also hear that you have started direct discussions with Pfizer, which is great news.  I expect us to send the agreed-upon letter this week so that we can finally provide you with the promised hands-on procurement support.

Re. your request on whether WB can finance Novovax via our AF, I am requesting Tania and Volkan to respond on the latest developments, but it is my understanding that we will be able to finance Novovax once it has received approval by three Stringent Regulatory Authorities (including by Emergency Use Authorization) in two Regions; or once Novovax receives the WHO Prequalification and has been approved (including by Emergency Use Authorization) by one Stringent Regulatory Authority.  And per our recent discussion, the chances of Novovax achieving this approval threshold is very high, though of course there is no 100% guarantee.  Note also that we can do retroactive financing for up to 40%.

Again, requesting Tania and Volkan to kindly follow-up.

Thank you and kind regards,

Sebastian

Sebastian Molineus
Regional Director for the South Caucasus
Europe and Central Asia
T  +995 (32) 291 6238
M +995 (577) 78 7821
M +1 (202) 492-3914
E  [email-masked]
W www.worldbank.org/en/region/eca

@smolineus

www.linkedin.com/in/molineus/

From: Tamar Gabunia <[email-masked]>
Sent: Sunday, April 4, 2021 7:50 PM
To: Sebastian-A Molineus <[email-masked]>; Volkan Cetinkaya <[email-masked]>; Nino Kvernadze <[email-masked]>; Nino V. Moroshkina <[email-masked]>; Enzo De Laurentiis <[email-masked]>
Cc: Tania Dmytraczenko <[email-masked]>; Ahmet Levent Yener <[email-masked]>; [email-masked]; [email-masked]; Giorgi Tsotskolauri <[email-masked]>; Maia Nikoleishvili <[email-masked]>; [email-masked]; Ekaterine Tikaradze <[email-masked]>
Subject: BFP for Novavax Contract-Georgia

[External]

Dear Sebastian

Dear Volkan

Colleagues

Many thanks for all your support to COVID 19 response so far. Since we are now working on planning the Covid 19 vaccination program within the WB financing, I would like to bring to your attention that the Ministry is currently negotiating with the Serum Institute of India on procuring 1million Novavax doses.  The Ministry intends to use World Bank’s financing for this procurement. Therefore, we would appreciate your guidance on terms and conditions of eligibility for the bank’s financing. Any assistance you may provide throughout the procurement process would be very helpful.

I look forward to receiving your feedback,

With kind regards

პატივისცემით,

თამარ გაბუნია

მინისტრის პირველი მოადგილე

Sincerely,

Tamar Gabunia, MD, MPH

First Deputy Minister